Carmell Therapeutics Stock Performance
| CTCXW Stock | 0.06 0 1.96% |
Carmell Therapeutics holds a performance score of 4 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.76, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Carmell Therapeutics will likely underperform. Use Carmell Therapeutics value at risk, as well as the relationship between the kurtosis and market facilitation index , to analyze future returns on Carmell Therapeutics.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Carmell Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Carmell Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 128.1 K | |
| Free Cash Flow | -8.4 M |
Carmell |
Carmell Therapeutics Relative Risk vs. Return Landscape
If you would invest 7.00 in Carmell Therapeutics on September 2, 2024 and sell it today you would lose (1.00) from holding Carmell Therapeutics or give up 14.29% of portfolio value over 90 days. Carmell Therapeutics is currently producing 1.6884% returns and takes up 29.8887% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Carmell, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Carmell Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Carmell Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Carmell Therapeutics, and traders can use it to determine the average amount a Carmell Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0565
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CTCXW | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 29.89 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.69 actual daily | 33 67% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Carmell Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Carmell Therapeutics by adding it to a well-diversified portfolio.
Carmell Therapeutics Fundamentals Growth
Carmell Stock prices reflect investors' perceptions of the future prospects and financial health of Carmell Therapeutics, and Carmell Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Carmell Stock performance.
| EBITDA | (15.19 M) | ||||
| Net Income | (15.45 M) | ||||
| Total Debt | 2.14 M | ||||
| Cash Flow From Operations | (8.35 M) | ||||
| Total Asset | 63.95 M | ||||
| Retained Earnings | (58.5 M) | ||||
| Working Capital | 24.4 M | ||||
About Carmell Therapeutics Performance
Evaluating Carmell Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Carmell Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Carmell Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.21) | (0.19) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.62) | (0.59) |
Things to note about Carmell Therapeutics performance evaluation
Checking the ongoing alerts about Carmell Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Carmell Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Carmell Therapeutics is not yet fully synchronised with the market data | |
| Carmell Therapeutics is way too risky over 90 days horizon | |
| Carmell Therapeutics has some characteristics of a very speculative penny stock | |
| Carmell Therapeutics appears to be risky and price may revert if volatility continues | |
| Carmell Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (15.45 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Carmell Therapeutics generates negative cash flow from operations | |
| Carmell Therapeutics has a frail financial position based on the latest SEC disclosures |
- Analyzing Carmell Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Carmell Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Carmell Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Carmell Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Carmell Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Carmell Therapeutics' stock. These opinions can provide insight into Carmell Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.